IXICO plc has completed a placing, subscription and retail offer
IXICO plc has raised US$5 million (£4.05 million) through an over-subscribed placing, subscription and retail offer, issuing 42,621,508 new ordinary shares at 9.5 pence per share, a premium to the price at the time. This important fundraising initiative enables the company to further its pioneering work in neuroscience through advanced imaging and data analytics.
IXICO is a leading medical imaging services provider, specializing in supporting clinical trials for pharmaceutical and biotech companies. With a global network of imaging sites and its custom TrialTracker platform, IXICO offers advanced imaging analytics and digital biomarker services for a variety of neurological diseases, including Alzheimer’s, Huntington’s, Parkinson’s and rare neurological disorders. The company is committed to regulatory compliance and has extensive experience in early-phase clinical development and extended longitudinal studies.
Oaklins Cavendish, one of Oaklins’ member firms in the UK, advised IXICO plc on this transaction.
Talk to the deal team
Related deals
Backspin has completed a mandatory public tender offer for the shares of Spindox
Backspin S.p.A. has completed a mandatory public tender offer for Spindox S.p.A.
Learn moreRare Patient Voice has been acquired by Konovo
Rare Patient Voice has been acquired by Konovo, a technology-first healthcare intelligence company backed by Fraser Healthcare Partners.
Learn moreLindenhofgruppe has sold its majority stake in LabPoint to Affidea Switzerland
LabPoint Medical Laboratories AG has been acquired by Affidea Switzerland AG. Through the transaction, Lindenhofgruppe AG gains a strong strategic partner to support the further development of LabPoint and will remain a shareholder with a reduced stake, continuing as a key customer of the company. It lays the foundation for LabPoint’s sustainable development under a new anchor shareholder, with the aim of further strengthening and selectively expanding its position in laboratory diagnostics.
Learn more